Real Options and Intellectual Property [electronic resource] :Capital Budgeting Under Imperfect Patent Protection / by Philipp N. Baecker.
by Baecker, Philipp N [author.]; SpringerLink (Online service).
Material type:
Item type | Current location | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|
MAIN LIBRARY | HG1-9999 (Browse shelf) | Available |
Browsing MAIN LIBRARY Shelves Close shelf browser
TA329-348 Neural Networks Theory | TP248.13-248.65 Analytics of Protein–DNA Interactions | LB1028.43-1028.75 Informatics Education – The Bridge between Using and Understanding Computers | HG1-9999 Real Options and Intellectual Property | TK5105.5-5105.9 Rigorous Development of Complex Fault-Tolerant Systems | HG1-9999 Real Options and Investment Incentives | Q334-342 Logic for Programming, Artificial Intelligence, and Reasoning |
Patenting Under Uncertainty -- Patent Protection, the Firm, and the Economy -- Uncertainty, Irreversibility, and Flexibility -- Patent Protection in the Pharmaceutical Industry -- Exogenous Patent Risk -- and Related Work -- Patents as Investment Opportunities -- Patent Risk as Jumps in the Underlying Process -- From Business Shifts to Jump Processes -- Preliminary Conclusion -- Endogenous Patent Risk -- and Related Work -- Patent Risk as an Option to Litigate -- Preliminary Conclusion -- Conclusion.
Over the last years, due to intensive competition in the knowledge economy, legal aspects surrounding intellectual property (IP) rights - including litigation and settlement - have continuously gained in importance. Correspondingly, professional IP management has become an indispensable element of successful value-based management (VBM) in research-intensive firms. With this text, the author proposes an integrated approach to patent risk and capital budgeting in pharmaceutical research and development (R and D), developing an option-based view (OBV) of imperfect patent protection, which draws upon contingent-claims analysis, stochastic game theory, as well as novel numerical methods. Bridging a widening gap between recent advances in the theory of financial analysis and current challenges faced by pharmaceutical companies, the text re-initiates a discussion about the contribution of quantitative frameworks to value-based R and D management.
There are no comments for this item.